within Pharmacolibrary.Drugs.ATC.L;

model L01XA04
  extends Pharmacokinetic.Models.PK_2C_enteral(
    weight         = 70,
    F              = 0.2,
    Cl             = 0.0012333333333333332,
    adminDuration  = 600,
    adminMass      = 120 / 1000000,   // mg → kg
    adminCount     = 1,
    Vd             = 0.314,
    Cmin           = 0.001,
    Cmax           = 0.01,
    Ctox_peak      = 0.02,
    Ctox_trough    = 0.01,
    ka             = 0.0031666666666666666,
    Tlag           = 10.200000000000001,            
    Vdp             = 0.453,
    k12             = 43,
    k21             = 43
    
  );

  annotation (Documentation(
    info       = "<html><body><table><tr><td>Drug:</td><td>L01XA04</td></tr><td>route:</td><td>oral</td></tr><tr><td>n-compartments</td><td>2</td></tr></table><p>Satraplatin is an oral platinum-based chemotherapeutic agent that was investigated for the treatment of advanced cancers, particularly prostate cancer. Unlike other platinum drugs such as cisplatin, satraplatin is orally bioavailable. Despite promising early-phase studies, satraplatin is not an approved drug today.</p><h4>Pharmacokinetics</h4><p>Pharmacokinetic parameters reported in adult cancer patients (typical age range 37-78 years) receiving oral satraplatin as monotherapy.</p><h4>References</h4><ol><li><p>Sova, P, et al., &amp; Chládek, J (2011). A comparative study of pharmacokinetics, urinary excretion and tissue distribution of platinum in rats following a single-dose oral administration of two platinum(IV) complexes LA-12 (OC-6-43)-bis(acetato)(1-adamantylamine)amminedichloroplatinum(IV) and satraplatin (OC-6-43)-bis(acetato)amminedichloro(cyclohexylamine)platinum(IV). <i>Cancer chemotherapy and pharmacology</i> 67(6) 1247–1256. DOI:<a href=\"https://doi.org/10.1007/s00280-010-1411-0\">10.1007/s00280-010-1411-0</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/20697713/\">https://pubmed.ncbi.nlm.nih.gov/20697713</a></p></li><li><p>Choy, H, et al., &amp; Yao, M (2008). Current status and future prospects for satraplatin, an oral platinum analogue. <i>Clinical cancer research : an official journal of the American Association for Cancer Research</i> 14(6) 1633–1638. DOI:<a href=\"https://doi.org/10.1158/1078-0432.CCR-07-2176\">10.1158/1078-0432.CCR-07-2176</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/18347164/\">https://pubmed.ncbi.nlm.nih.gov/18347164</a></p></li><li><p>Vouillamoz-Lorenz, S, et al., &amp; Decosterd, LA (2003). Pharmacokinetics of satraplatin (JM216), an oral platinum (IV) complex under daily oral administration for 5 or 14 days. <i>Anticancer research</i> 23(3C) 2757–2765. PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/12926110/\">https://pubmed.ncbi.nlm.nih.gov/12926110</a></p></li></ol></body></html>",
    revisions  = "<html><body><ul><li>06/2025 initial model generated by LLM gpt-4.1 from general data</li></ul></body></html>"
  ));
end L01XA04;
